Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 15151910)

1.

Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.

Ashton D, Kim P, Griffiths N, Beran R.

Age Ageing. 2004 Jul;33(4):408-9. Epub 2004 May 19.

2.
3.

Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice.

Jain NK, Patil CS, Kulkarni SK, Singh A.

Behav Brain Res. 2002 Jul 18;133(2):369-76.

PMID:
12110471
4.

Aseptic meningitis associated with rofecoxib.

Bonnel RA, Villalba ML, Karwoski CB, Beitz J.

Arch Intern Med. 2002 Mar 25;162(6):713-5.

PMID:
11911727
5.
6.

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Laine L, Maller ES, Yu C, Quan H, Simon T.

Gastroenterology. 2004 Aug;127(2):395-402.

PMID:
15300570
8.

Aseptic meningitis associated with chronic sulindac use for osteoarthritis: a case report.

Callen EC, Church CO, Patel M, Sikes TL.

Rheumatol Int. 2008 Feb;28(4):391-3. Epub 2007 Aug 17.

PMID:
17703306
9.
10.

Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.

Senna G, Bilò MB, Antonicelli L, Schiappoli M, Crivellaro MA, Bonadonna P, Dama AR.

Eur Ann Allergy Clin Immunol. 2004 Jun;36(6):215-8.

PMID:
15329003
11.

Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.

Bannwarth B, Ravaud P, Dougados M.

J Rheumatol. 2003 Feb;30(2):421-2. No abstract available.

12.

Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance.

Muñoz-Bellido FJ, Terrón M, León A.

Allergy. 2003 Oct;58(10):1072-5. No abstract available.

PMID:
14510733
13.

Anti-inflammatory drugs in the 21st century.

Rainsford KD.

Subcell Biochem. 2007;42:3-27. Review.

PMID:
17612044
14.

The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.

Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):437-41. Erratum in: Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):669.

PMID:
15937867
15.

COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.

Davies NM, Jamali F.

J Pharm Pharm Sci. 2004 Oct 29;7(3):332-6.

16.

Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Savage R.

Drugs Aging. 2005;22(3):185-200. Review.

PMID:
15813652
17.

COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.

Hochberg MC.

Curr Top Med Chem. 2005;5(5):443-8. Review.

PMID:
15974939
18.

Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.

Bouée S, Charlemagne A, Fagnani F, Le Jeunne P, Sermet C, Naudin F, Lancry PJ.

Joint Bone Spine. 2004 May;71(3):214-20.

PMID:
15182793
19.

[Is there a future for COX-2 inhibitors?].

Yodfat Y.

Harefuah. 2004 Nov;143(11):820-4, 837. Review. Hebrew.

PMID:
15603272
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk